GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spago Nanomedical AB (XSAT:SPAG BTA) » Definitions » Tariff Resilience Score

Spago Nanomedical AB (XSAT:SPAG BTA) Tariff Resilience Score : 0/10 (As of Jul. 23, 2025)


View and export this data going back to . Start your Free Trial

What is Spago Nanomedical AB Tariff Resilience Score?

Spago Nanomedical AB has the Tariff Resilience Score of 0, which implies that the company might have .

Spago Nanomedical AB has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Spago Nanomedical AB might have .


Spago Nanomedical AB  (XSAT:SPAG BTA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Spago Nanomedical AB Tariff Resilience Score Related Terms

Thank you for viewing the detailed overview of Spago Nanomedical AB's Tariff Resilience Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Spago Nanomedical AB Business Description

Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, SE-223 63
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.

Spago Nanomedical AB Headlines

No Headlines